N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial

  • Jerome Sarris (Creator)
  • Gerard J. Byrne (Creator)
  • David Castle (Creator)
  • Chad Bousman (Creator)
  • Georgina Oliver (Creator)
  • Lachlan Cribb (Creator)
  • Scott Blair-West (Creator)
  • Vlasios Brakoulias (Creator)
  • David Camfield (Creator)
  • Carolyn Ee (Creator)
  • Suneel Chamoli (Creator)
  • Mark Boschen (Creator)
  • Olivia Dean (Creator)
  • Nathan Dowling (Creator)
  • Ranjit Menon (Creator)
  • Jenifer Murphy (Creator)
  • Joelle Metri (Creator)
  • Thomas Nguyen (Creator)
  • Andrew Wong (Creator)
  • Rebecca Jordan (Creator)
  • Diana Karamacoska (Creator)
  • Susan L. Rossell (Creator)
  • Michael Berk (Creator)
  • Chee H. Ng (Creator)

    Dataset

    Description

    This study seeks to elucidate the benefits of NAC augmentation (2-4 grams/day) compared to placebo in the treatment of OCD, in a 24-week, multi-centre, randomized, double-blind, placebo controlled trial. It is hypothesized that NAC will be superior over placebo for improving OCD symptoms as measured by a reduction in Y-BOCS scores from baseline against each subsequent time point (W4, W8, W12, W16, W20 and W24). Additional benefits are anticipated for relieving anxiety as well as improving mood, functioning and overall quality of life.

    The dataset relates to the clinical trial ACTRN12616000847415 N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. This data cannot be shared publicly due to ethics approval conditions.

    To discuss this data, please contact the NICM Health Research Institute [email protected].
    Date made available1 Apr 2025
    PublisherWestern Sydney University
    Date of data production15 Nov 2017 - 30 Jun 2020

    Cite this